Carboplatin and etoposide (CE) chemotherapy in patients with recurrent or progressive oligodendroglial tumors

Journal of Neuro-Oncology

Volumn 79, Issue 3, 2006, Pages 299-305

  Scopece, Luciano ^a   Franceschi, Enrico ^a   Cavallo, Giovanna ^a   Paioli, Anna ^a   Paioli, Gabriele ^a   Conforti, Rosa ^a   Palmerini, Emanuela ^a   Berzioli, Carlotta ^a   Spagnolli, Federica ^a   Esposti, Roberta Degli ^a   Crinò, Lucio ^a  

^a BELLARIA HOSPITAL   (Italy)

Author keywords

Carboplatin; Chemotherapy; Etoposide; Oligodendroglial tumors

Indexed keywords

ANTICONVULSIVE AGENT; ANTIEMETIC AGENT; CARBOPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; FOTEMUSTINE; IMATINIB; PREDNISOLONE; STEROID; TEMOZOLOMIDE; VINCRISTINE;

ADULT; AGE DISTRIBUTION; AGED; ANAPLASTIC CARCINOMA; AREA UNDER THE CURVE; ARTICLE; ASTROCYTOMA; BLOOD TOXICITY; BRAIN RADIATION; BRAIN TUMOR; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE ACTIVITY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; GLIOBLASTOMA; HUMAN; INFECTION; MALE; NEUROSURGERY; NEUTROPENIA; OLIGODENDROGLIA; OLIGODENDROGLIOMA; PHASE 2 CLINICAL TRIAL; THROMBOCYTOPENIA; TUMOR RECURRENCE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CARBOPLATIN; DISEASE-FREE SURVIVAL; ETOPOSIDE; FEMALE; GLIOMA; HUMANS; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 33748532842     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-006-9144-y     Document Type: Article

References (19)

1. Chinot OL, Honore S, Dufour H, Barrie M, Figarella-Branger D, Muracciole X, Braguer D, Martin PM, Grisoli F (2001) Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. J Clin Oncol 19(9):2449-2455
2. van den Bent MJ, Chinot O, Boogerd W, Boogerd W, Bravo Marques J, Taphoorn MJ, Kros JM, van der Rijt CC, Vecht CJ, De Beule N, Baron B (2003) Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972. Ann Oncol 14(4):599-602
3. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8(7):1277-1280
4. Friedman HS, Lovell S, Rasheed K, Friedman AH (1998) Treatment of adults with progressive oligodendroglioma with carboplatin (CBDCA): Preliminary results. Writing committee for The Brain Tumor Center at Duke. Med Pediatr Oncol 31(1):16-18
5. 5Franceschi E, Cavallo G, Scopece L, Paioli A, Pession A, Magrini E, Conforti R, Palmerini E, Bartolini S, Rimondini S, Degli Esposti R, Crinò L (2004) Phase II trial of carboplatin and etoposide for patients with recurrent high-grade glioma. Br J Cancer 91(6):1038-1044
6. Jeremic B, Grujicic D, Jevremovic S, Stanisavljevic B, Milojevic L, Djuric L, Mijatovic L (1992) Carboplatin and etoposide chemotherapy regimen for recurrent malignant glioma: A phase II study. J Clin Oncol 10:1074-1077
7. Boiardi A, Silvani A, Milanesi I, Botturi M, Broggi G (1991) Primary glial tumor patients treated by combining cisplatin and etoposide. J Neuro-oncol 11:165-170
8. Buckner JC, Brown LD, Cascino TL, Gerstner JB, Krook JE, Westberg MW, Wiesenfeld M, O'Fallon JR, Scheithauer B (1990) Phase II evaluation of infusional etoposide and cisplatin in patients with recurrent astrocytoma. J Neuro-oncol 9:249-254
9. Stein ME, Kuten A, Drumea K, Goldsher D, Tzuk-Shina Z (1999) Carboplatin and Etoposide for recurrent malignant gliomas following surgical and radiotherapy failure: A clinical study conducted at the Northern Israel Oncology Center. J Surg Oncol 71:167-170
10. Fulton D, Urtasun R, Forsyth P (1996) Phase II study of prolonged oral therapy with etoposide (VP16) for patients with recurrent malignant glioma. J Neurooncol 27(2):149-155
11. Kiya K, Uozumi T, Ogasawara H, Sugiyama K, Hotta T, Mikami T, Kurisu K (1992) Penetration of etoposide into human malignant brain tumors after intravenous and oral administration. Cancer Chemother Pharmacol 29(5): 339-342
12. Postmus PE, Holthuis JJ, Haaxma-Reiche H, Mulder NH, Vencken LM, van Oort WJ, Sleijfer DT, Sluiter HJ (1984) Penetration of VP 16-213 into cerebrospinal fluid after high-dose intravenous administration. J Clin Oncol 2(3):215-220
13. Brandes AA, Basso U, Vastola F, Tosoni A, Pasetto LM, Jirillo A, Lonardi S, Paris MK, Koussis H, Monfardini S, Ermani M (2003) Carboplatin and teniposide as third-line chemotherapy in patients with recurrent oligodendroglioma or oligoastrocytoma: A phase II study. Ann Oncol 14(12):1727-1731
14. Peterson K, Paleologos N, Forsyth P, Macdonald DR, Cairncross JG (1996) Salvage chemotherapy for oligodendroglioma. J Neurosurg 85:597-601
15. Brandes AA, Tosoni A, Vastola F, Pasetto LM, Coria B, Danieli D, Iuzzolino P, Gardiman M, Talacchi A, Ermani M (2004) Efficacy and feasibility of standard procarbazine, lomustine, and vincristine chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy. A Phase II study. Cancer 101(9):2079-2085
16. van den Bent MJ, Kros JM, Heimans JJ, Pronk LC, van Groeningen CJ, Krouwer HG, Taphoorn MJ, Zonnenberg BA, Tijssen CC, Twijnstra A, Punt CJ, Boogerd W (1998) Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group. Neurology 51(4):1140-1145
17. van den Bent MJ, Taphoorn MJ, Brandes AA, Menten J, Stupp R, Frenay M, Chinot O, Kros JM, van der Rijt CCD, Vecht ChJ, Allgeier A, Gorlia T (2003) Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: The European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. J Clin Oncol 21(13):2525-2528
18. Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, Silver JS, Stark PC, Macdonald DR, Ino Y, Ramsay DA, Louis DN (1998) Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90:1473-1479
19. Ino Y, Betensky RA, Zlatescu MC, Sasaki H, Macdonald DR, Stemmer-Rachamimov AO, Ramsay DA, Cairncross JG, Louis DN (2001) Molecular subtypes of anaplastic oligodendroglioma: Implications for patient management at diagnosis. Clin Cancer Res 7:839-845